Abstract
Governments around the world are responding to the novel coronavirus (COVID-19) pandemic1 with unprecedented policies designed to slow the growth rate of infections. Many actions, such as closing schools and restricting populations to their homes, impose large and visible costs on society. In contrast, the benefits of these policies, in the form of infections that did not occur, cannot be directly observed and are currently understood through process-based simulations.2–4 Here, we compile new data on 936 local, regional, and national anti-contagion policies recently deployed in the ongoing pandemic across localities in China, South Korea, Iran, Italy, France, and the United States (US). We then apply reduced-form econometric methods, commonly used to measure the effect of policies on economic growth, to empirically evaluate the effect that these anti-contagion policies have had on the growth rate of infections. In the absence of any policy actions, we estimate that early infections of COVID-19 exhibit exponential growth rates of roughly 45% per day. We find that anti-contagion policies collectively have had significant effects slowing this growth, although policy actions in the US appear to be too recent to have a substantial impact since the magnitude of these effects grows over time. Our results suggest that similar policies may have different impacts on different populations, but we obtain consistent evidence that the policy packages now deployed are achieving large and beneficial health outcomes. We estimate that, to date, current policies have already prevented or delayed on the order of eighty-million infections. These findings may help inform whether or when ongoing policies should be lifted or intensified, and they can support decision-making in the over 150 countries where COVID-19 has been detected but not yet achieved high infection rates.5
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
SAP, EK, PL, JT are supported by a gift from the Tuaropaki Trust. TC is supported by an AI for Earth grant from National Geographic and Microsoft. DA, AH, IB are supported through joint collaborations with the Climate Impact Lab. KB is supported by the Royal Society Te Aparangi Rutherford Postdoctoral Fellowship (New Zealand). HD and ER are supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE 1106400 and 1752814, respectively. Opinions, findings, conclusions or recommendations expressed in this material are those of the authors and do not reflect the views of supporting organizations. The authors declare no conflicts of interest.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and code used in this analysis are available at https://github.com/bolliger32/gpl-covid. Updates are posted at http://www.globalpolicy.science/covid19.